Arrowhead Pharmaceuticals (ARWR) Income Statement
Arrowhead Pharmaceuticals Income Statement
Last quarter (Q3 2026), Arrowhead Pharmaceuticals's total revenue was $75.25M, an increase of 171.02% from the same quarter last year. In Q3, Arrowhead Pharmaceuticals's net income was $-194.28M. See Arrowhead Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Sep 25 | Sep 24 | Sep 23 | Sep 22 | Sep 21 |
|---|---|---|---|---|---|
| $ 829.45M | $ 3.55M | $ 240.74M | $ 243.23M | $ 138.29M | |
| $ 829.45M | $ -15.04M | $ 228.24M | $ 232.81M | $ 138.29M | |
| $ 731.10M | $ 586.04M | $ 433.24M | $ 411.32M | $ 287.32M | |
| Depreciation and Amortization | $ 23.93M | $ 18.59M | $ 12.49M | $ 10.42M | $ 8.27M |
| $ 164.82M | $ -561.51M | $ -175.67M | $ -162.29M | $ -132.58M | |
| $ 98.35M | $ -601.08M | $ -205.00M | $ -178.51M | $ -149.04M | |
| $ -46.81M | $ -11.38M | $ -1.49M | $ 5.80M | $ 8.19M | |
| $ 51.53M | $ -612.46M | $ -206.49M | $ -172.71M | $ -140.85M | |
| $ -1.63M | $ -599.49M | $ -205.28M | $ -176.06M | $ -140.85M | |
| Per Share Metrics | |||||
| Basic EPS | $ -0.01 | $ -5.00 | $ -1.92 | $ -1.67 | $ -1.36 |
| Diluted EPS | $ -0.01 | $ -5.00 | $ -1.92 | $ -1.67 | $ -1.36 |
| Weighted Average Shares Outstanding | 133.76M | 119.78M | 106.75M | 105.43M | 103.75M |
| Weighted Average Shares Outstanding (Diluted) | 133.76M | 119.78M | 106.75M | 105.43M | 103.75M |
Currency in USD